Landec Corporation  

(Public, NASDAQ:LNDC)   Watch this stock  
Find more results for LNDC
-0.01 (-0.08%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.41 - 11.97
52 week 10.38 - 15.16
Open 11.70
Vol / Avg. 148,386.00/117,439.00
Mkt cap 317.91M
P/E 25.09
Div/yield     -
EPS 0.47
Shares 27.03M
Beta 1.26
Inst. own 95%
Mar 29, 2016
Q3 2016 Landec Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 6, 2016
Q2 2016 Landec Corp Earnings Call - Webcast
Jan 5, 2016
Q2 2016 Landec Corp Earnings Release
Dec 9, 2015
Landec Corp at Wedbush Securities California Dreamin' Technology Consumer Management Access Conference
Dec 9, 2015
Landec Corp at Goldman Sachs US Financial Services Conference
Dec 9, 2015
Landec Corp at ROTH Utah Healthy / Active Lifestyle Corporate Access Event
Nov 18, 2015
Landec Corp at Three Part Advisors Southwest IDEAS Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Nov '15) 2015
Net profit margin 1.37% 2.55%
Operating margin 2.00% 3.42%
EBITD margin - 4.74%
Return on average assets 2.20% 4.16%
Return on average equity 3.35% 6.43%
Employees 550 -
CDP Score - -


3603 Haven Ave
MENLO PARK, CA 94025-1010
United States - Map
+1-650-3061650 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Landec Corporation designs, develops, manufactures and sells differentiated products for food and biomaterials markets and licenses technology applications to partners. The Company's segments include Food Products Technology, Food Export and Hyaluronan-based Biomaterials. The Company's Food Products Technology segment markets and packs specialty packaged whole and fresh-cut fruit and vegetables. The Company's Food Export segment is engaged in the purchase and sale of whole commodity fruit and vegetable products to Asia and domestically. The Company's Hyaluronan-based Biomaterials segment sells products utilizing hyaluronan, a polysaccharide that is distributed in the extracellular matrix of connective tissues in both animals and humans, for medical use primarily in the ophthalmic, orthopedic and veterinary markets. The Company licenses its Intellicoat seed coatings to the farming industry and licenses its Intelimer polymers for personal care products and other industrial products.

Officers and directors

Steven D. Goldby Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Molly A. Hemmeter President, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Gregory S. Skinner Chief Financial Officer, Vice President - Finance and Administration
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Nicholas Tompkins Chairman of the Board of Apio, Inc., Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald Lane Midyett Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Steven P. Bitler Ph.D. Vice President - Corporate Technology
Age: 57
Bio & Compensation  - Reuters
Larry D. Hiebert Vice President, President of Lifecore Biomedical, Inc.
Age: 59
Bio & Compensation  - Reuters
Albert D. Bolles Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Frederick Frank Independent Director
Age: 83
Bio & Compensation  - Reuters
R. Dean Hollis Independent Director
Age: 54
Bio & Compensation  - Reuters